Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

nsb asx

  • Home
  •  
  • nsb asx



  • Most Read
  • Latest Comments
  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s
    • News

    NeuroScientific Biopharmaceuticals make major breakthrough towards treating Alzheimer’s

    With the average person’s life expectancy rising, Alzheimer’s disease is emerging as a major health concern which can have devastating effects on an individual’s cognitive function. It leads to progressive loss of brain cells which later leads to loss of memory and has become a global menace, costing the world over US$818 billion in treatment

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.